TY - JOUR
T1 - IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy
AU - Humbert, Marc
AU - Bousquet, Jean
AU - Bachert, Claus
AU - Palomares, Oscar
AU - Pfister, Pascal
AU - Kottakis, Ioannis
AU - Jaumont, Xavier
AU - Thomsen, Simon Francis
AU - Papadopoulos, Nikolaos G.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
AB - Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
KW - Omalizumab
KW - Asthma
KW - Multimorbidities
KW - Treatment
KW - Allergic rhinitis
KW - Rhinoconjunctivitis
KW - Chronic rhinosinusitis with nasal polyps
KW - Vernal keratoconjunctivitis
KW - Food allergies
KW - Allergic bronchopulmonary aspergillosis
U2 - 10.1016/j.jaip.2019.02.030
DO - 10.1016/j.jaip.2019.02.030
M3 - Review
C2 - 30928481
SN - 2213-2198
VL - 7
SP - 1418
EP - 1429
JO - The Journal of Allergy and Clinical Immunology: In Practice
JF - The Journal of Allergy and Clinical Immunology: In Practice
IS - 5
ER -